Media
Media
Julien Willard speaks and writes on AI in drug development, biotech dealmaking, and the economics of global health. Recent appearances and writing are below, with a short bio for producers and hosts.
Bio
Julien Willard, MD, MPH, is a physician-economist and biopharma strategist. He advises life-sciences leadership on strategy, transactions, and operations, and has worked on more than $35 billion in biopharma deals. He founded Arcstone Strategy Group and is head of research and investments at BioPalace. Before that he led life-sciences strategy at IBM and ran corporate strategy for North America biotech at Accenture. Earlier still, he ran global-health programs at the World Bank. He lives in San Diego.
Topics
AI in pharmaceutical R&D and clinical-trial design. Biotech M&A and licensing, including China and broader APAC deal flow. The economics of drug access and global health. How biopharma leaders turn strategy into execution.
Selected appearances
- Game of Pharma — how China reshaped global pharma and biotech licensing
- Life Sciences Today — intelligence tradecraft applied to pharma strategy
- The Chris Hood Digital Show — data strategy and managing AI bias
- CXO Dispatch — harnessing AI in pharma (video)
- Storytelling vs Math — how narratives shape biotech investment
- Claiming Your Own Success — career and leadership
- NY Weekly — optimizing problem-solving with AI
He also hosts Take as Directed, a podcast in which biopharma executives debate the industry’s hardest problems.
Selected writing
- Gómez & Willard, “Explaining Russia’s Struggle to Eradicate HIV/AIDS,” Journal of Comparative Policy Analysis, 2020
- Clinical-trial optimization with AI and AI for clinical-trial management, IBM
- Precision medicine with IBM and Amazon Omics, IBM
- “Financing the last mile in global polio eradication,” World Bank, 2017 (published as Oleg Kucheryavenko)
Booking
To book Julien for a podcast, panel, or interview, get in touch. A headshot is available on request.
